Enrich your medicines pipeline - Domainex provides a complete range of preclinical drug discovery services tailored to meet all your research needs
Location: United Kingdom, England
Employees: 51-200
Founded date: 2001
Investors 2
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | Juno Capit... | junocapita... |
Mentions in press and media 13
| Date | Title | Description |
| 14.01.2026 | Nuclera Accelerates AI-Driven Antibody Engineering with $87 Million Capital Infusion | Nuclera secures an additional $12 million, elevating Series C funding to $87 million. This critical capital fuels accelerated antibody engineering on its eProtein Discovery benchtop system. The biotech leader targets AI-enabled protein deve... |
| 13.01.2026 | UK’s Nuclera brings Series C funding to €74 million following €10 million extension for its eProtein Discovery system | Cambridge-based Nuclera, a BioTech company accelerating drug discovery by providing access to functional proteins through its benchtop eProtein Discovery System, today announced a €10 million ($12 million) financing extension, bringing the ... |
| 13.01.2026 | Nuclera Extends Series C Funding To $87 Million To Advance Antibody Engineering | Nuclera, a biotech company developing a benchtop platform for rapid access to functional proteins, has raised a $12 million extension to its Series C financing, bringing total Series C funding to $87 million. The extension was led by Elevag... |
| 31.05.2023 | Drug Discovery Services Market Set to Reach Valuation of USD 44.91 Billion by 2030, Size, Share, Demand, Future Growth, Challenges and Competitive Analysis | Data Bridge Market Research analyses that the drug discovery services market, which was USD 14.68 billion in 2022, is expected to reach USD 44.91 billion by 2030, at a CAGR of 15.00% during the forecast period 2023 to 2030 /EIN News/ -- NEW... |
| 31.05.2023 | Drug Discovery Services Market Set to Reach Valuation of USD 44.91 Billion by 2030, Size, Share, Demand, Future Growth, Challenges and Competitive Analysis | - |
| 07.02.2022 | Drug Discovery Services Market to reach a valuation of US$ 50.9 Bn by 2032 - Comprehensive Research Report by FMI | DUBAI, United Arab Emirates, Feb. 07, 2022 (GLOBE NEWSWIRE) -- As per a recent report published by Future Market Insights, the global demand for drug discovery services is expected to rise at a 14.5% CAGR to acquire a valuation of US$ 50.9 ... |
| 03.02.2022 | MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson's program | Synaffix and MacroGenics have signed a deal to codevelop and commercialize a clinical platform for antibody-drug conjugates to fight cancer. Synaffix will license out its GlycoConnect antibody conjugation platform, polar spacer technology a... |
| 16.03.2018 | Longtime R&D chief Bischofberger leaves Gilead; Novartis operations chief heads out; Astellas taps Barretto-Ko to run Americas operations | Norbert Bischofberger → After a stretch of close to 30 years at Gilead $GILD, longtime R&D chief Norbert Bischofberger is leaving the company. He’ll be stepping out at the end of April, the latest in a whirlwind series of... |
| 26.01.2016 | Domainex and Cresset announce drug discovery services alliance | Domainex and Cresset announce drug discovery services alliance 26-01-2016 Domainex and Cresset alliance will provide customers with world-class laboratory-based and computational drug discovery services through a seamless combination of the... |
| 20.04.2015 | Queen’s University Belfast & Domainex collaborate to advance novel lung cancer drug research | Queen’s University Belfast & Domainex collaborate to advance novel lung cancer drug research 20-04-2015 Dr Dan Longley’s research team at Queen’s University Belfast, and Domainex Ltd., specialists in drug discovery solutionsand translat... |
Show more